evidencegaps
Search

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

741 questions · 808 findings · 27 reviews · Oral medicine and oral cancer · related questions CL0289

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 95 · 11.8%GRADE not reported 498 · 61.6%Very low 134 · 16.6%Low 53 · 6.6%Moderate 27 · 3.3%High 1 · 0.1%

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash

Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone

Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.

1 finding from 1 review

Amifostine vs no treatment/placebo

Dysgeusia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine led to lower dysgeusia (grade >= 2, 0-4 scale) compared with no treatment/placebo; GRADE not reported.

1 finding from 1 review

Zinc supplements vs Acupuncture

Outcome not reported · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)

The review found no eligible studies for this question.

1 finding from 1 review
  • Interventions for managing taste disturbances 2017 · Cochrane All outcomes
    Authors' conclusions: We were unable to draw any conclusions regarding the superiority of zinc supplements or acupuncture as none of the trials compared these interventions.
    0 studies
    No studies found

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single dose) vs Granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple doses)

Normalcy of diet (total parenteral nutrition) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers

Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Palifermin showed no clear difference in overall survival compared with placebo (moderate certainty).

1 finding from 1 review

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

Survival (overall survival and locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review

Amifostine (intravenous) vs Amifostine (subcutaneous)

Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine (intravenous) showed no clear difference in locoregional tumour control compared with amifostine (subcutaneous); GRADE not reported.

1 finding from 1 review

Pilocarpine vs no treatment/placebo

Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Pilocarpine led to lower xerostomia (objective, LENT-SOMA scale) compared with no treatment/placebo; GRADE not reported.

3 findings from 1 review

Zinc vs placebo

Taste acuity improvement - objective outcome (continuous) - individual taste sensations · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)

Zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… showed no clear difference in taste acuity improvement - objective outcome (continuous) -… compared with placebo; GRADE not reported.

1 finding from 1 review
  • Interventions for managing taste disturbances 2017 · Cochrane All outcomes
    Chronic renal failure
    Results (Mahajan 1980, chronic renal failure; Analysis 1.3): mean difference by taste sensation - salt MD 285 (95% CI 238.75 to 331.25); sweet MD 190 (142.36 to 237.64); sour MD 10 (-16.43 to 36.43); bitter MD 2.40…
    1 study · 22 participants
    GRADE not reported

Amifostine vs no treatment/placebo

Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Amifostine may leads to lower xerostomia (grade >= 2, 0-4 scale) compared with no treatment/placebo (low certainty).

3 findings from 1 review

Polaprezinc vs Azulene oral rinse

Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.

1 finding from 1 review

G‐CSF vs placebo or no treatment

Oral mucositis (any severity) · Adults with cancer receiving treatment

Granulocyte-colony stimulating factor (G-CSF) led to lower oral mucositis (any severity) compared with placebo or no treatment; GRADE not reported.

2 findings from 1 review

Antimicrobial lozenge vs placebo

Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

Antimicrobial lozenge showed no clear difference in xerostomia compared with placebo; GRADE not reported.

1 finding from 1 review

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Oral mucositis (moderate to severe) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).

3 findings from 1 review